Linked Life Data

19505217

Source:http://linkedlifedata.com/resource/pubmed/id/19505217

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
9
pubmed:dateCreated
2009-6-9
pubmed:abstractText
Lupus nephritis, one of the most severe and therapeutically challenging manifestations of systemic lupus erythematosus (SLE), has been the target of drug development by La Jolla Pharmaceutical Company. Abetimus sodium, an example of the La Jolla Pharmaceutical Company's Tolerance Technology is an intravenously administered tetrameric oligonucleotide conjugate that safely reduces antidouble-stranded DNA (anti-dsDNA) antibodies. Given the importance of anti-dsDNA antibodies in the pathogenesis of lupus nephritis, the Phase II and III trials were designed to evaluate whether treatment with abetimus sodium could prolong the time to renal flare in cohorts of patients at high risk of nephritic flares.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
1744-7666
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
10
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1501-7
pubmed:meshHeading
pubmed:year
2009
pubmed:articleTitle
Abetimus sodium: a medication for the prevention of lupus nephritis flares.
pubmed:affiliation
Division of Rheumatology and Allergy-Clinical Immunology, North Shore-Long Island Jewish Health System, Lake Success, NY 11042, USA.
pubmed:publicationType
Journal Article, Review